vs
Side-by-side financial comparison of Ameriprise Financial (AMP) and Boston Scientific (BSX). Click either name above to swap in a different company.
Boston Scientific is the larger business by last-quarter revenue ($5.2B vs $4.9B, roughly 1.1× Ameriprise Financial). Boston Scientific runs the higher net margin — 25.7% vs 18.7%, a 7.0% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 9.0%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 5.5%).
Ameriprise Financial, Inc., through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. It operates through four segments: Advice & Wealth Management, Asset Management, Retirement & Protection Solutions, and Corporate & Other. The Advice & Wealth Management segment provides financial planning and advice; brokerage products and services for retail and institutional clients; discretionary and non-di...
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
AMP vs BSX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.9B | $5.2B |
| Net Profit | $915.0M | $1.3B |
| Gross Margin | — | 69.5% |
| Operating Margin | — | — |
| Net Margin | 18.7% | 25.7% |
| Revenue YoY | 9.0% | 11.6% |
| Net Profit YoY | 57.0% | 99.0% |
| EPS (diluted) | — | $0.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.9B | $5.2B | ||
| Q4 25 | $5.0B | $5.3B | ||
| Q3 25 | $4.9B | $5.1B | ||
| Q2 25 | $4.5B | $5.1B | ||
| Q1 25 | $4.5B | $4.7B | ||
| Q4 24 | $4.6B | $4.6B | ||
| Q3 24 | $4.6B | $4.2B | ||
| Q2 24 | $4.4B | $4.1B |
| Q1 26 | $915.0M | $1.3B | ||
| Q4 25 | $1.0B | $670.0M | ||
| Q3 25 | $912.0M | $755.0M | ||
| Q2 25 | $1.1B | $795.0M | ||
| Q1 25 | $583.0M | $672.0M | ||
| Q4 24 | $1.1B | $563.0M | ||
| Q3 24 | $511.0M | $468.0M | ||
| Q2 24 | $829.0M | $322.0M |
| Q1 26 | — | 69.5% | ||
| Q4 25 | — | 69.6% | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | 67.7% | ||
| Q1 25 | — | 68.8% | ||
| Q4 24 | — | 67.8% | ||
| Q3 24 | — | 68.8% | ||
| Q2 24 | — | 69.2% |
| Q1 26 | — | — | ||
| Q4 25 | 25.6% | 15.6% | ||
| Q3 25 | 24.0% | 20.7% | ||
| Q2 25 | 30.1% | 16.2% | ||
| Q1 25 | 15.3% | 19.8% | ||
| Q4 24 | 29.1% | 14.8% | ||
| Q3 24 | 14.1% | 17.4% | ||
| Q2 24 | 23.9% | 12.6% |
| Q1 26 | 18.7% | 25.7% | ||
| Q4 25 | 20.0% | 12.7% | ||
| Q3 25 | 18.6% | 14.9% | ||
| Q2 25 | 23.6% | 15.7% | ||
| Q1 25 | 13.0% | 14.4% | ||
| Q4 24 | 23.0% | 12.3% | ||
| Q3 24 | 11.2% | 11.1% | ||
| Q2 24 | 18.9% | 7.8% |
| Q1 26 | — | $0.90 | ||
| Q4 25 | $10.39 | $0.45 | ||
| Q3 25 | $9.33 | $0.51 | ||
| Q2 25 | $10.73 | $0.53 | ||
| Q1 25 | $5.83 | $0.45 | ||
| Q4 24 | $10.57 | $0.38 | ||
| Q3 24 | $5.00 | $0.32 | ||
| Q2 24 | $8.02 | $0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.3B | — |
| Total DebtLower is stronger | $3.3B | — |
| Stockholders' EquityBook value | $355.9B | — |
| Total Assets | $184.4B | — |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $8.3B | — | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $534.0M | ||
| Q1 25 | — | $725.0M | ||
| Q4 24 | — | $414.0M | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.9B |
| Q1 26 | $3.3B | — | ||
| Q4 25 | — | $11.1B | ||
| Q3 25 | — | $11.1B | ||
| Q2 25 | — | $11.1B | ||
| Q1 25 | — | $10.5B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $9.0B |
| Q1 26 | $355.9B | — | ||
| Q4 25 | $6.5B | $24.2B | ||
| Q3 25 | $6.5B | $23.4B | ||
| Q2 25 | $6.1B | $22.4B | ||
| Q1 25 | $5.4B | $22.2B | ||
| Q4 24 | $5.2B | $21.8B | ||
| Q3 24 | $5.7B | $20.7B | ||
| Q2 24 | $5.0B | $20.4B |
| Q1 26 | $184.4B | — | ||
| Q4 25 | $190.9B | $43.7B | ||
| Q3 25 | $190.1B | $42.7B | ||
| Q2 25 | $184.9B | $41.6B | ||
| Q1 25 | $179.1B | $40.1B | ||
| Q4 24 | $181.4B | $39.4B | ||
| Q3 24 | $186.0B | $38.1B | ||
| Q2 24 | $179.7B | $37.1B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMP
| Management and financial advice fees | $2.9B | 60% |
| Other | $872.0M | 18% |
| Distribution fees | $563.0M | 12% |
| Premiums, policy and contract charges | $341.0M | 7% |
| Other revenues | $166.0M | 3% |
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
